Kezar presents zetomipzomib safety update from PALIZADE Phase 2b lupus nephritis trial

Kezar Life Sciences, Inc.

KOL event hosted by William Blair covering zetomipzomib in autoimmune hepatitis and lupus nephritis.
Safety update from PALIZADE Phase 2b trial (active lupus nephritis) disclosed at event; no specific data provided.
No financial results, guidance changes, or regulatory decisions announced.
Company undertakes no obligation to update the presentation materials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.